Analysts at Barrington Research initiated coverage on Rosetta Genomics Ltd. (USA) ROSG with a Outperform rating.
The target price for Rosetta Genomics is set to $8.
Rosetta Genomics shares have dropped 15.23 percent over the past 52 weeks, while the S&P 500 index has surged 11.85 percent in the same period.
Rosetta Genomics' shares rose 1.80 percent to $3.40 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in